Full Breakdown
Netflix Executive Sues Over Termination After Ketamine Disclosure
7/28/2026, 2:09:35 AM
Core Event: Termination Following Ketamine Disclosure
Kevin Baillie, the former vice president and head of creative at Eyeline Studios—Netflix’s visual-effects division—has filed a wrongful-termination lawsuit alleging that his dismissal was triggered by his disclosure of medically prescribed ketamine use. Baillie says he was terminated in April 2026 after a company-wide “Vulnerability-Trust” exercise at a Netflix-owned retreat in January 2026, during which he explained that he had undergone physician-supervised ketamine therapy in October and November 2022 to treat clinical depression following his mother’s death.
Background & Context: Trust Exercise and Workplace Culture
The January 2026 retreat took place at Sendero Ranch, a private property in Northern California owned by Netflix. The “Vulnerability-Trust” exercise was designed to encourage employees to share personal experiences. According to the complaint, Baillie’s admission of ketamine treatment was followed by an internal inquiry that framed his medical disclosure as potentially recreational drug use.
The filing describes a broader workplace environment in which Eyeline Studios CEO Jeff Shapiro allegedly maintained a personal bar in his office, served alcohol to staff after meetings with Netflix co-CEO Ted Sarandos, and brought beer on company outings. Baillie recounts that, during the same retreat, he performed a stunt—drinking a pint of Guinness while standing on his head—after a colleague requested a demonstration.
Timeline
- January 2026 – “Vulnerability-Trust” exercise at Sendero Ranch; Baillie discloses ketamine therapy.
- April 2026 – Baillie is terminated from his $1.1 million-a-year position.
Data & Statistics
- Annual salary: $1.1 million (approximately £820,000).
- Severance claim: Baillie alleges he was denied up to one year of severance pay.
- Compensation sought: The complaint requests compensatory damages, lost wages, damages for emotional distress, punitive damages, and a jury trial.
Official Statements & Responses
Netflix has not provided a comment to the press outlets reporting the lawsuit.
Legal Claims and Requested Relief
The lawsuit contends that Baillie’s termination violated his rights because the ketamine treatment was prescribed and administered under medical supervision. The complaint frames the internal investigation as inconsistent with the company’s alleged permissive drinking culture, arguing that Baillie was subjected to a double standard. Baillie seeks a jury trial and monetary relief covering lost wages, emotional distress, and punitive damages.
Impact and Broader Implications
If the court finds in Baillie’s favor, the case could set a precedent for how employers handle disclosures of legally prescribed psychiatric treatments, especially in environments that promote openness through trust-building activities. The lawsuit also highlights potential tensions between corporate culture—particularly informal alcohol consumption—and employee privacy rights. Stakeholders in the entertainment and tech sectors may monitor the outcome for guidance on policy development around medical disclosures and workplace investigations.
